AstraZeneca Tops FTSE 100 Risers on Drug Progress
AstraZeneca Gains After Breast-Cancer Drug Progress
0845 GMT - Shares in AstraZeneca top the FTSE 100 risers, up
2.7% after the drug company reported further success in trials of a
cancer drug. AstraZeneca said Enhertu significantly delayed
metastatic breast-cancer progression in a Phase 3 trial,
reinforcing the results of a previous study. "Pharmaceutical shares
were marked sharply higher in early exchanges following an
announcement from AstraZeneca regarding the trial success of its
breast-cancer drug, Enhertu," Interactive Investor Head of Markets
Richard Hunter writes. "The news had a positive read-across to the
rest of the sector in underlining the potential strides the major
pharmaceutical companies are now making."
Treatt Lowers FY 2022 Pretax Profit Guidance Amid Inflation,
Weaker US Consumer Sentiment
Treatt PLC said Monday that it is lowering its adjusted pretax
profit guidance for fiscal 2022 after being hurt by a number of
factors including lower consumer confidence in the U.S. and cost
Echo Energy Raises GBP600,000 via Share Placing
Echo Energy PLC said Monday that it has now raised 600,000
pounds ($728,280) via the share placing announced on Friday.
Phoenix Group on Track to Achieve Top End of 2022
Phoenix Group Holdings PLC said Monday that first-half operating
profit remained at a similar level on a year-on-year basis and that
it is on track to meet the top end of its full-year cash generation
Safestay Swung to 2021 Pretax Profit After Lifting of Covid-19
Safestay PLC said Monday that it swung to a pretax profit for
2021 after Covid-19-related restrictions were lifted.
TP Group 2021 Pretax Loss Widened on Higher Costs; Refinancing
Process to Start in 2H
TP Group PLC said Monday that its 2021 pretax loss widened on
higher costs, and that the board will start a group refinancing
process in the second half of 2022 and will consider both debt and
Inspiration Healthcare 1H Performance Robust on Strong Order
Inspiration Healthcare Group PLC said in an update Monday that
performance has remained robust and consistent with management
expectations for the six months ended July 31.
Eckoh PLC 1Q Orders Were Substantially Higher on Year
Eckoh PLC said Monday that orders for the first quarter of the
current fiscal year were substantially higher than the same period
a year earlier and that it expects to report a significantly higher
level for the half year.
Gusbourne 1H Revenue More Than Doubled as Sales Recovered From
Gusbourne PLC said Monday that revenue for the first six months
of 2022 more than doubled, driven by a recovery in sales from
Seeing Machines Sees in-Line FY 2022 Revenue on Accelerated
Seeing Machines Ltd. said in a performance update Monday that it
foresees reporting revenue in line with expectations for fiscal
2022 after growth momentum accelerated.
Joules New CEO Might Face a Difficult Task Amid Squeezed
0906 GMT - The new CEO of Joules, Jonathon Brown, will face a
difficult task ahead given the inflationary backdrop and the
squeezed household budgets, AJ Bell's financial analyst Danni
Hewson. The U.K. lifestyle brand is facing the challenge of being
in the middle of this pressure, neither serving wealthy
customers--which could expend on luxury brands--nor offering
bargains that could attract lower income clients, Hewson says.
UK Housing Market Starting to Slow But Shares Don't Budge
0845 GMT - The U.K. property market is starting to show signs of
softening, as Rightmove's latest survey indicates house prices
slipped in August, AJ Bell says. It feels like a long-overdue
return to Earth given the macroeconomic backdrop, yet shares in
house builders barely budged on the news, indicating the market
might have already factored in a slowdown, AJ Bell financial
analyst Danni Hewson says in a research note. "However, strong
selling prices have been the one thing insulating the sector from
rising costs so it will be worth keeping tabs on future trading
updates to see if margins are coming under pressure," the U.K.
brokerage says. Shares in Barratt Developments, Persimmon and
Taylor Wimpey are down 0.8%, 0.5% and 0.4% respectively.
Phoenix Group's 1H Performance Seen as Solid With No
0848 GMT - Phoenix Group's overall solid print in 1H came
without surprises and therefore investors' focus might switch
toward an organic dividend increase and the M&A pipeline, Citi
analyst Andrew Baker says in a research note. The European life
insurer reported a cash generation 37% above market consensus and
seems to be well set for an organic dividend increase, Baker says.
"Phoenix shares are up 7% year-to-day outperforming the broader
insurance sector by around 9 percentage points," he says. The U.S.
bank has a neutral recommendation on the stock and a target price
of 618.0 pence. (email@example.com)
Contact: London NewsPlus; firstname.lastname@example.org
(END) Dow Jones Newswires
August 15, 2022 05:29 ET (09:29 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
From Aug 2022 to Sep 2022
From Sep 2021 to Sep 2022